Table 1.
Summary of All Treatment-Emergent AEs
| Category, n (%) | Lorlatinib (n = 25) | Crizotinib (n = 22)a |
|---|---|---|
| Any AE | 25 (100.0) | 22 (100.0) |
| Serious AEs | 8 (32.0) | 7 (31.8) |
| Grade 3/4 AEs | 21 (84.0) | 16 (72.7) |
| Fatal AEs | 1 (4.0) | 0 |
| Discontinued from study due to AEs | 1 (4.0) | 0 |
| Discontinued study treatment due to AEs | 4 (16.0) | 6 (27.3) |
| Dose reduction or temporary discontinuation due to AEs | 17 (68.0) | 17 (77.3) |
AE, adverse event.
a
Safety end points were assessed in the safety analysis set, which included all patients who received more than or equal to one dose of the study treatment.